Skip to main content

Table 1 Several individual markers are differentially methylated between the prognostic groups and neuroblastoma risk factors

From: Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers

Type

Subtype

KRT19

FAS

PRPH

CNR1

QPCT

HIST1H3C

ACSS3

GRB10

Prognostic group

LR-SURV

0/31 (0%)

1/31 (3%)

14/31 (45%)

2/31 (6%)

18/31 (58%)

0/31 (0%)

0/31 (0%)

6/31 (19%)

 

HR-SURV

14/30 (48%)

8/30 (27%)

24/30 (80%)

10/30 (33%)

25/30 (83%)

2/30 (7%)

14/30 (47%)

13/30 (43%)

 

HR-DOD

9/28 (32%)

6/28 (21%)

19/28 (68%)

10/28 (36%)

24/28 (86%)

6/28 (21%)

7/28 (25%)

11/28 (39%)

Stage

Stage 1

0/21 (0%)

0/21 (0%)

8/21 (38%)

1/21 (5%)

13/21 (62%)

0/21 (0%)

0/21 (0%)

4/21 (19%)

 

Stage 2

1/12 (8%)

2/12 (17%)

8/12 (67%)

2/12 (17%)

8/12 (67%)

0/12 (0%)

1/12 (8%)

3/12 (25%)

 

Stage 3

9/17 (53%)

4/17 (24%)

13/17 (77%)

9/17 (53%)

15/17 (88%)

3/17 (18%)

9/17 (58%)

8/17 (47%)

 

Stage 4

13/39 (33%)

9/39 (15%)

28/39 (72%)

10/39 (26%)

31/39 (80%)

5/39 (18%)

11/39 (28%)

15/39 (39%)

MYCN

MYCN single copy

7/50 (14%)

2/50 (4%)

24/50 (48%)

5/50 (10%)

31/50 (62%)

0/50 (0%)

2/50 (4%)

14/50 (28%)

 

MYCN amplified

16/39 (41%)

13/39 (33%)

33/39 (85%)

17/39 (44%)

36/39 (92%)

8/39 (21%)

19/39 (49%)

16/39 (41%)

Age

Age at diagnosis > 12 months

21/53 (40%)

14/53 (26%)

37/53 (69%)

18/53 (34%)

46/53 (87%)

8/53 (15%)

21/53 (40%)

24/53 (45%)

 

Age at diagnosis < 12 months

2/36 (6%)

1/36 (3%)

20/396(56%)

4/36 (11%)

21/36 (58%)

0/36 (0%)

0/36 (0%)

6/36 (17%)

 

Age at diagnosis > 18 months

20/45 (44%)

13/45 (29%)

33/45 (73%)

17/45 (38%)

40/45 (89%)

8/45 (18%)

19/45 (49%)

23/45 (51%)

 

Age at diagnosis < 18 months

3/44 (7%)

2/44 (5%)

24/44 (55%)

5/44 (11%)

27/44 (61%)

0/44 (0%)

2/44 (5%)

7/44 (16%)

Overall total

 

23/89 (26%)

15/89 (17%)

57/89 (64%)

22/89 (25%)

67/89 (75%)

8/89 (9%)

21/89 (24%)

30/89 (34%)

Statistics (Fisher's exact P-value)

         

Prognostic group

 

<0.001

0.151

0.112

0.068

0.165

0.0624

<0.001

0.405

MYCN

 

0.0594

0.008

0.008

0.008

0.017

0.0146

<0.001

0.708

Stage

 

0.007

0.287

0.221

0.059

0.683

0.448

0.008

0.700

Age cutoff 12 months

 

0.008

0.045

0.579

0.138

0.059

0.123

<0.001

0.059

Age cutoff 18 months

 

0.002

0.045

0.326

0.059

0.045

0.0594

0.0015

0.012

  1. The number (percentage) of methylated samples in each stratum is given. P-values according to the Fisher's exact test, corrected for multiple testing (Benjamini-Hochberg). HR-DOD, high-risk deceased patients; HR-SURV, high-risk patients alive for at least 1,000 days follow-up; LR-SURV, low-risk patients alive for at least 1,000 days follow-up. P-values in bold indicate significant associations.